You searched for "prostate"
Use of MRI in the evaluation of prostate cancer: part 2
Diffusion weighted imaging and contrast enhanced imaging Introduction Magnetic resonance imaging (MRI) is widely used in localisation, staging and post-treatment follow-up of prostate cancer. In the previous issue, we discussed the usefulness of MRI in depicting prostate anatomy and pairing...Use of MRI in the evaluation of prostate cancer: part 1
Introduction Prostate cancer remains the most commonly diagnosed cancer in males and the second leading cause of cancer related deaths in UK men, after lung cancer [1]. The incidence of prostate cancer in the UK has shown a rapid increase...
Patient-reported outcomes after prostate cancer treatment
1 January 2015
| Ann Crump
|
URO - Urologic Oncology
This study used the survivorship (LIVESTRONG) care plan tool to identify patient-reported toxicities that occurred following treatment for prostate cancer. All patients had undergone treatments, which were considered to have similar oncological endpoints. The tool asked patients questions with regard...
Recent advances in the management of castration resistant prostate cancer
1 November 2017
| Styliani Germanou, Sophie Merrick, Simon Chowdhury
|
URO - Urologic Oncology
Castrate resistant prostate cancer (CRPC) is defined by disease progression despite androgen-deprivation therapy lowering testosterone to castrate levels. It may present as a rise in serum levels of prostate specific antigen (PSA), progression of pre-existing disease, or the appearance of...
An update on antibiotic prophylaxis in TRUS-guided prostate biopsy
1 November 2016
| Dafader MS Hossain, Tamani Jayawardhana, Sanjeev Madaan
|
URO - Urologic Oncology, URO - Infection
Since its inception in the 1980s, transrectal ultrasound (TRUS)-guided prostate biopsy has remained the standard tool for the histological diagnosis of prostate cancer. There are several advantages to this technique which have led to the widespread use of TRUS in...
Day-case monopolar and bipolar transurethral resection of the prostate
1 September 2015
| Ann Crump
|
URO - Endourology & Stones
The aim of this study was to assess the safety and efficacy of performing monopolar (mTURP) and bipolar transurethral resection of prostate (bTURP) as a day-case. This was a prospective two-centre study. One centre performed day-case mTURP (group M) and...
Prostate cancer survivorship: a new path for uro-oncology
1 July 2015
| Sanchia S Goonewardene, Raj Persad (Prof), Veronica Nanton, Annie Young (Prof), Adel Makar
|
URO - Urologic Oncology
Over two million people in England have a diagnosis of cancer [1]. Of this figure, over 250,000 have been diagnosed with prostate cancer [2]. However, during the next decade, a rapid increase in the number of new cancer diagnoses, as...
Sexual dysfunction following prostate cancer treatment
4 March 2024
| Maria Harrington-Vogt, Aditya Manjunath, Nader Gaballa, Odunayo M Kalejaiye
|
URO - Andrology, URO - Urologic Oncology
Prostate cancer is common with over 52,300 new cases diagnosed annually in the UK; this is expected to rise by 15% between 2023-2025 and 2038-2040 [1]. Radical prostatectomy continues to be the most common form of radical treatment for men...
Can antibiotics reduce ‘unnecessary’ prostate biopsies?
1 March 2014
| Mark Harris
|
URO - Urologic Oncology
With numerous factors capable of influencing prostate specific antigen (PSA) levels and therefore the likelihood of biopsy, this multi-centred randomised controlled trial (RCT) was designed to see if two weeks of ciprofloxacin compared to placebo would significantly reduce PSA levels...
Prostate biopsies without antibiotic cover – are we there yet?
12 October 2022
| Karthik Rajan
|
URO - Core Urology
Transperineal (TP) prostate biopsies are widely replacing the traditional transrectal route due to definite evidence of reduced infective complications. TP biopsies are usually performed with a single dose of antibiotic pre-procedure in most centres. In this article the authors attempt...
Prostate Cancer Diagnosis – PSA, Biopsy and Beyond
The danger of many of the texts which deal with this rapidly changing field is that by the time the texts are published they are out of date. This book however remains fresh, in part because it acknowledges that there...
The potential of statin use in castrate resistant prostate cancer treatment
1 May 2016
| Pravisha Ravindra
|
URO - Urologic Oncology
One of the mechanisms by which prostate cancer achieves castrate resistance is through de novo intratumoral production of androgens. Reactivation of androgen receptors results in promotion of cell survival and proliferation pathways despite castrate serum testosterone levels. As androgen synthesis...
